Financiere de Tubize SA TUB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €220.00
- Day Range
- €218.40–223.80
- 52-Week Range
- €168.10–250.50
- Bid/Ask
- €215.20 / €223.20
- Shares Outstanding
- 44.51M
- Market Cap
- €9.83B
- Volume/Avg
- 18,742 / 20,643
Key Statistics
- Price/Earnings (Normalized)
- 99.51
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.49%
- Dividend Yield (Forward)
- 0.49%
- Dividend Payment Schedule
- May
- Total Yield
- 0.49%
Company Profile
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a world-wide biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. The company generates majority of its sales revenue is derived from its neurology products, followed by its immunology products. The company's plan focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 250
- Website
- https://www.financiere-tubize.be
Valuation
|
Metric
|
TUB
|
|---|---|
Price/Earnings (Normalized) | 99.51 |
Price/Book Value | 4.93 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
TUB
Financial Strength
|
Metric
|
TUB
|
|---|---|
Quick Ratio | 233.59 |
Current Ratio | 233.59 |
Interest Coverage | — |
Quick Ratio
TUB
Profitability
|
Metric
|
TUB
|
|---|---|
Return on Assets (Normalized) | 5.04% |
Return on Equity (Normalized) | 5.08% |
Return on Invested Capital (Normalized) | 5.07% |
Return on Assets
TUB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|x&d#d? | LOCK|mfkF% | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|##>?J> | LOCK|DP#C% | $84B | |||
| Moderna Inc
MRNA
| LOCK|@MV<>t | LOCK|z@ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|sQXbcT | LOCK|ptj | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<KkF$B | LOCK|^? | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@tK%#< | LOCK|SzWWS | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gMLL<>! | LOCK|#LLjl | $29B | |||
| Incyte Corp
INCY
| LOCK|?Z$<VFt | LOCK|Rq | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|^zxVCv | LOCK|xM | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|T<g<!<N | LOCK|Hv | $14B |
United States